866-997-4948(US-Canada Toll Free)

Parkinson`s Disease Pipeline Assessment and Market Forecasts to 2016

Published By :

GlobalData

Published Date : Jun 2010

Category :

Therapeutic Area

No. of Pages : 55 Pages


GlobalData, the industry analysis specialists new report, Parkinsons Disease Pipeline Assessment and Market Forecasts to 2016 is an essential source of information and analysis on the global Parkinsons disease market. The report identifies the key trends shaping and driving the global Parkinsons disease market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global Parkinsons disease sector. GlobalData estimated the global Parkinsons disease market to be valued at $3,178m in 2009. It is forecast to grow at 0.9% annually for the next seven years to reach $3,384m by 2016. This low growth is ascribed to patent expirations, subsequent entry of generics, weak developmental pipeline and the unknown cause of the disease continues to pose significant challenges for prospective market entrants, is expected to keep the market static. Ageing population would be a key driver of this market. The global Parkinsons disease market is not well served with current product options and boundless scope is available to new entrants that would capture value from underserved segments. Designing disease-modifying drugs rather than drugs for providing symptomatic relief is one of the key challenges of this market and could provide significant market for any company. GlobalData finds that the global Parkinsons disease market is increasingly hampered by lack of innovation. On the whole, the late stage pipeline consists of drugs that are aimed at the symptomatic treatment of the disease. There are 181 products in different developmental stages in 2010. Majorly, pipeline presents drugs that are aimed at symptomatic treatment of the disease. Balancing the pipeline with the huge burden of the disease and high expectations of patients, the pipeline is considered to be weak. If a company wants to capture this unmet need, it will need to overcome the prevailing product weaknesses and adverse effects such as dyskinesis, psychiatric side effects and obsessive compulsive behaviors. Currently, these are the biggest challenges preventing most pipeline products from capturing these unmet needs.

Scope

The scope of the report includes: 

  • Annualized global Parkinsons disease market revenues data from 2001 to 2009, forecast forward for 7 years to 2016. 
  • Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends. Key classes of mechanism of action includes dopamine agonists, adenosine receptor antagonists, serotonin receptor targetters, glutamate receptor antagonists, NMDA receptor targetters, AMPA receptor antagonists, stem cell and gene therapy. 
  • Analysis of the current and future market competition in the global Parkinsons disease market. Key future market players covered are Merck Serono, Acadia Pharmaceuticals, Axxonis Pharma AG, Avicena Group Inc., and Solvay Pharmaceuticals. 
  • Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications. 
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with Parkinsons disease.
Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to
 
  • Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline. 
  • Develop business strategies by understanding the trends shaping and driving the global Parkinsons disease market. 
  • Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global Parkinsons disease market in future. 
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. 
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. 
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. 
  • Whats the next big thing in the global Parkinsons disease market landscape? Identify, understand and capitalize.
Table Of Contents

1 Table of contents 3
1.1 List of Tables 5
1.2 List of Figures 5

2 Parkinsons Disease Market: Market Characterization 6
2.1 Overview 6
2.2 Parkinsons Disease Market Size 6
2.3 Parkinsons Disease Market Forecast and CAGR 7
2.4 Drivers and Barriers for the Parkinsons Disease Market 8
2.4.1 Drivers for the Parkinsons Disease Market 8
2.4.2 Barriers for the Parkinsons Disease Market 8
2.5 Opportunity and Unmet Need 9
2.5.1 Key Takeaway 10

3 Parkinsons Disease Market: Competitive Assessment 11
3.1 Overview 11
3.2 Strategic Competitor Assessment 11
3.3 Product Profile for the Major Marketed Products in the PD Market 12
3.3.1 Stalevo (levodopa, carbidopa, entacapone) 12
3.3.2 Requip XL (ropinirole XL) 13
3.3.3 Azilect (rasagiline mesylate) 14
3.3.4 Mirapex/Sifrol/Mirapexin (pramipexole dihydrochloride) 15
3.4 Other Marketed Products for the Parkinsons Disease Market 16
3.4.1 Comtan (entacapone) 16
3.4.2 Tasmar (tolcapone) 16
3.5 Key Takeaway 19

4 Parkinsons Disease Market: Pipeline Assessment 20
4.1 Overview 20
4.2 Strategic Pipeline Assessment 20
4.2.1 Technology Trends Analytic Framework 20
4.3 Parkinsons Disease Therapeutics Promising Drugs under Clinical Development 22
4.4 Molecule Profile for Promising Drugs under Clinical Development 23
4.4.1 Safinamide 23
4.4.2 Pimavanserin (ACP-103) 24
4.4.3 PD-02 25
4.4.4 SLV 308 (pardoprunox) 25
4.4.5 Lisuride (patch and subcutaneous (sc) infusion) 26
4.4.6 IPX066 27
4.5 Parkinsons Disease Therapeutics Market Clinical Pipeline by Mechanism of Action 28
4.6 Parkinsons Disease Pipeline Pipeline by Clinical Phases of Development 28
4.6.1 Parkinsons Disease Therapeutics Phase III Clinical Pipeline 29
4.6.2 Parkinsons disease Therapeutics Phase II Clinical Pipeline 31
4.6.3 Parkinsons Disease Therapeutics Phase I Clinical Pipeline 33
4.6.4 Parkinsons Disease Therapeutics Preclinical Pipeline 34
4.6.5 Parkinsons Disease Therapeutics Discovery Pipeline 35
4.7 Discontinued / Suspended Drugs for Parkinsons Disease 36
4.8 Key Takeaway 37

5 Parkinsons Disease Market: Implications for Future Market Competition 38

6 Parkinsons Disease Market: Future Players in the Parkinsons Disease Market 40
6.1 Introduction 40
6.2 Merck Serono 40
6.2.1 Overview 40
6.2.2 CNS Portfolio 40
6.2.3 Parkinsons Disease Product Portfolio 41
6.3 Acadia Pharmaceuticals 42
6.3.1 Overview 42
6.3.2 CNS Portfolio 42
6.3.3 Parkinsons Disease Product Portfolio 42
6.4 Axxonis Pharma AG 43
6.4.1 Overview 43
6.4.2 CNS Portfolio 43
6.4.3 Parkinsons Disease Product Portfolio 43
6.5 Avicena Group Inc. 44
6.5.1 Overview 44
6.5.2 CNS Portfolio 44
6.5.3 Parkinsons Disease Product Portfolio 45
6.6 Solvay Pharmaceuticals 45
6.6.1 Overview 45
6.6.2 CNS Portfolio 45
6.6.3 Parkinsons Disease Product Portfolio 46
6.7 Impax Laboratories 47
6.7.1 Overview 47
6.7.2 CNS Portfolio 47
6.7.3 Parkinsons Disease Product Portfolio 47

7 Parkinsons Disease Market: Appendix 49
7.1 Market Definitions 49
7.2 Abbreviations 49
7.3 Research Methodology 50
7.3.1 Coverage 51
7.3.2 Secondary Research 51
7.3.3 Forecasting 51
7.3.4 Primary Research 53
7.3.5 Expert Panel Validation 54
7.4 Contact Us 54
7.5 Disclaimer 54
7.6 Sources 54

List of Table

 
Table 1: Global Parkinsons Disease Market Revenue($m) Forecast 20012009 7
Table 2: Global Parkinsons Disease Market Revenue($m) Forecast 20092016 8
Table 3: Major Marketed Products Comparison in the Parkinsons Disease Market, 2010 18
Table 4: Parkinsons Disease Therapeutics Most Promising Drugs under Clinical Development, 2010 22
Table 5: Parkinsons Disease Therapeutics Phase III Clinical Pipeline, 2010 29
Table 6: Parkinsons Disease Therapeutics Phase II Clinical Pipeline, 2010 31
Table 7: Parkinsons Disease Therapeutics Phase I Clinical Pipeline, 2010 33
Table 8: Parkinsons Disease Therapeutics Preclinical Pipeline, 2010 34
Table 9: Parkinsons Disease Therapeutics Discovery Pipeline, 2010 35
Table 10: List of Discontinued Drugs for Parkinsons Disease, 2010 36
Table 11: Merck Serono CNS Marketed Products, 2010 40
Table 12: Merck Serono CNS Pipeline Products, 2010 41
Table 13: Acadia Pharmaceuticals CNS Pipeline Products, 2010 42
Table 14: Axxonis Pharma AG CNS Pipeline Products, 2010 43
Table 15: Avicena Group Inc. CNS Pipeline Products, 2010 44
Table 16: Solvay Pharmaceuticals CNS Marketed Products, 2010 45
Table 17: Solvay Pharmaceuticals CNS Pipeline Products, 2010 46
Table 18: Impax Laboratories CNS Marketed Products, 2010 47
Table 19: Impax Laboratories CNS Pipeline Products, 2010 47

List of Chart

 
Figure 1: Global Parkinsons Disease Market Revenue($m) Forecast 20012009 7
Figure 2: Global Parkinsons Disease Market Revenue($m) Forecast 20092016 8
Figure 3: Opportunity and Unmet Need in the Parkinsons Disease Market, 2010 10
Figure 4: Strategic Competitor Assessment of the Major Marketed Products in Parkinsons Disease, 2010 11
Figure 5: Technology Trends Analytic Framework of the Parkinsons Disease Pipeline, 2010 21
Figure 6: Technology Trends Analytic Framework of the Parkinsons Disease Pipeline Description, 2010 21
Figure 7: Parkinsons Disease Therapeutics Market Clinical Pipeline by Mechanism of Action, 2010 28
Figure 8: Parkinsons Disease Pipeline Pipeline by Clinical Phases of Development, 2010 28
Figure 9: Implications for Future Market Competition in the Parkinsons Disease Market, 2010 38
Figure 10: Parkinsons Disease Therapeutics Market Clinical Pipeline by Company, 2010 40
Figure 11: GlobalData Methodology 50
Figure 12: GlobalData Market Forecasting Model 53

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *